Shigehiro Yagishita

8PUBLICATIONS
55CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 28, 2026
Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models.

|Jul 15, 2026
Preclinical Evaluation of Liposomal Eribulin (E7389-LF) in a Panel of Sarcoma Patient-Derived Xenograft Models.

|Jun 23, 2025
Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models.

Shigehiro Yagishita, Sho Sato, Daisuke Shintani

|Feb 12, 2025
Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma.

Sho Sato, Daisuke Shintani, Yuki Kaneda

|Jun 18, 2024
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older.

Shigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata

|Mar 28, 2023
Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy.

Shigehiro Yagishita, Tadaaki Nishikawa, Hiroshi Yoshida

Pageof 2

Frequent Collaborators

4 joint publications

Akinobu Hamada

3 joint publications

Sho Sato

3 joint publications

Kosei Hasegawa

3 joint publications

Masanori Yasuda